A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules

Autor: Antonella Borrelli, Piero Pucci, Andrea Carpentieri, F. Tuccillo, Marina Sanseverino, Viviana De Luca, P. Bonelli, Leila Birolo, Antonietta Schiattarella, Jean Rommelaere, Alessandra Pica, Enrico Gori, Roberto Mancini, Maria Laura Pollio, Clemente Capasso, Maria Grazia Ruggiero, Aldo Mancini
Přispěvatelé: Borrelli, A., Schiattarella, A., Mancini, R., Pica, Alessandra, Pollio, MARIA LAURA, Ruggiero, MARIA GRAZIA, Bonelli, P., De Luca, V., Tuccillo, F. M., Capasso, Clemente, Gori, E., Sanseverino, M., Carpentieri, Andrea, Birolo, Leila, Pucci, Pietro, Rommelaere, J., Mancini, A.
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Zdroj: Scientific reports (Nature Publishing Group) 6 (2016). doi:10.1038/srep18691
info:cnr-pdr/source/autori:Borrelli, Antonella; Schiattarella, Antonietta; Mancini, Roberto; Pica, Alessandra; Pollio, Maria Laura; Ruggiero, Maria Grazia; Bonelli, Patrizia; De Luca, Viviana; Tuccillo, Franca Maria; Capasso, Clemente; Gori, Enrico; Sanseverino, Marina; Carpentieri, Andrea; Birolo, Leila; Pucci, Piero; Rommelaere, Jean; Mancini, Aldo/titolo:A new hexapeptide from the leader peptide of rMnSOD enters cells through the oestrogen receptor to deliver therapeutic molecules/doi:10.1038%2Fsrep18691/rivista:Scientific reports (Nature Publishing Group)/anno:2016/pagina_da:/pagina_a:/intervallo_pagine:/volume:6
Scientific Reports
DOI: 10.1038/srep18691
Popis: A 24-amino acid leader peptide of a new human recombinant manganese superoxide dismutase can enter cells and carry molecules. Here, we demonstrated that six of the 24 amino acids penetrate cells through a particular gate represented by a specific amino acid sequence of the oestrogen receptor (ER). We analysed the internalization of the synthetic hexapeptide and the cytotoxic activity of the hexapeptide conjugated to cisplatin on a cell line panel. In most cell lines, the hexapeptide delivered an amount of cisplatin that was 2 to 8 times greater than that released by cisplatin when the drug was used alone. This increased delivery increases the therapeutic index of cisplatin and reduces side effects caused by a high dosage or long-term treatment times. We may consider this hexapeptide a new molecular carrier to deliver molecules with therapeutic activity into ER+ cells for diagnostic purposes and clinical or immune therapy.
Databáze: OpenAIRE